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Materials and methods: The experimental group included 16 cases of OSCC without metastasis and
7 cases of OSCCwith metastasis. The presence or absence of nodal metastasis was used as a parameter
for the evaluation of disease prognosis. Ten cases of oral fibroepithelial hyperplasia were selected as
the control group. The expression of BMP-2/4 and BMPR-IAwas analyzed by immunohistochemistry.
Results: In the experimental group with metastasis, strong expression of BMP-2/4 was observed in
most cases (71.4%), whereas BMPR-IA exhibited weak expression (85.7%). In the experimental
group without metastasis, there was strong expression of BMP-2/4 (62.5%) and BMPR-IA (100%).
A significant association was observed between the prognosis of OSCC and the intensity of BMP-
2/4 staining (P = .002). Weak immunoreactivity to BMP-2/4 and BMPR-IA was observed in all
control specimens.
Conclusions: The results suggest that strong expression of BMP-2/4, associated with low
expression of BMPR-IA, observed in metastatic OSCC has a prognostic value, with the loss of
responsiveness to BMPs through the loss of expression of their receptors being indicative of the
development of metastasis.
© 2010 Published by Elsevier Inc.1. Introduction
Bone morphogenetic proteins (BMPs) are pleiotropic
cytokines of the transforming growth factor β family [1].
These proteins are components of an evolutionarily con-
served signaling system and are involved in the regulation of
cell growth, differentiation, apoptosis, chemotaxis, angio-
genesis, and matrix production both during embryo and
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009.03.002Studies in the areas of embryology, genetics, and
carcinogenesis have demonstrated that disturbances in the
BMP signaling pathway contribute to the development of
neoplasms. The first evidence of this involvement arose from
genetic studies on familial cancer syndromes such as familial
juvenile polyposis, in which mutations in Smad-4 and
BMPR-IA have been implicated in the origin of the disease.
In addition, the BMP signaling pathway is found to be
altered in sporadic human cancers. The action of these
proteins during carcinogenesis is complex and involves both
protumor and antitumor activities, depending on the stage of
the disease [4].
During the initial phase of neoplastic development, BMPs
inhibit the cell cycle by stimulating the overexpression of
protein p21, a universal inhibitor of cyclin-dependent
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kinase complex results in the inhibition of the kinase activity
of the latter and consequently paralyzes cell cycle progres-
sion [5]. The protumor activity of BMPs occurs in more
advanced stages of neoplastic development and favors the
dissemination of metastasis by inducing the expression of
vascular endothelial growth factor (VEGF), thus exerting a
proangiogenic effect. Therefore, elevated expression of these
cytokines in tumors might be significantly associated wit a
poor prognosis [6-8].
The role of BMPs in the development of epithelial tumors
is still uncertain, and various studies have investigated their
mechanisms of action in different tissues of the human
organism. In view of the scarcity of reports investigating
these proteins in oral epithelial tumors, the present study
analyzed the immunohistochemical expression of BMP-2/4
and its receptor BMPR-IA in metastatic and nonmetastatic
oral squamous cell carcinoma (OSCC) and its implications
for disease prognosis.ig. 1. Overexpression of BMP-2/4 in nonmetastatic OSCC (arrows)
(original magnification ×400).2. Materials and methods
The sample consisted of 23 squamous cell carcinoma
specimens involving different sites in the oral cavity. The
specimens were obtained from incisional biopsies stored in
the archives of Hospital Dr Luís Antônio, Natal, Rio Grande
do Norte, Brazil. These specimens were divided into 2
groups: a nonmetastatic group consisting of 16 OSCC cases
without nodal or distant metastasis and a metastatic group
consisting of 7 cases of OSCC with nodal and distant
metastasis. The parameter presence or absence of nodal and
distant metastasis was collected from the patient records
based on the TNM staging system and was used for the
selection of the OSCC cases and the evaluation of disease
prognosis. For the control group, 10 specimens of fibroe-
pithelial hyperplasia were selected among excisional biop-
sies involving different sites in the oral cavity. The
specimens were obtained from the archives of the Patholo-
gical Anatomy Service, Discipline of Oral Pathology,
Dentistry School, Federal University of Rio Grande do
Norte (UFRN).
Histologic sections (3 μm thick) were obtained from the
selected material and submitted to immunohistochemistry by
the streptavidin-biotin method. Bone morphogenetic protein-
2/4 and its receptor BMPR-IA were first reconstituted in 1
mL sterile phosphate-buffered saline each, pH 7.6, and
immunohistochemistry was performed after 24 hours. For
this, the paraffin-embedded sections were deparaffinized in
xylene and rehydrated in a decreasing ethanol series.
Endogenous tissue peroxidase was blocked by 2 baths of 5
minutes each in 10 volumes of 6% hydrogen peroxide in
methanol (1:1, vol/vol). Antigens were retrieved with 0.1%
trypsin and 0.1% CaCl2 in Tris for 30 minutes at 37°C. After
incubation in normal serum for 30 minutes, the sections were
incubated with the following primary antibodies: BMP-2/4(AF355) and BMPR-IA (AF346) (both from R&D Systems,
Inc, Minneapolis, MN, USA, overnight at 4°C and 1:50).
The LSAB peroxidase kit (Dako Corporation, Glostrup,
Denmark) was used as secondary antibody and tertiary
complex for the 2 proteins studied. The reaction was
developed with 0.3% diaminobenzidine (Sigma Chemical
Co, St Louis, MO, USA) diluted in Tris, pH 7.4, and
activated with 600 mL 6% hydrogen peroxide in a dark
chamber for 3 minutes. The sections were then washed under
running water and in distilled water and counterstained with
Mayer's hematoxylin for 10 minutes. Human cartilage was
used as positive control, and samples in which the primary
antibody was omitted and replaced with buffered 1% bovine
serum albumin were used as negative control. Positive and
negative controls were processed as described above.
Immunoreactivity to BMP-2/4 and BMPR-IA was
analyzed qualitatively in a double-blind fashion by 2
observers. Only the epithelial component of the selected
specimens was examined. Scores of 1 (weak expression) and
2 (strong expression), adapted from Wakulich et al [9], were
used for analysis.
Expression of the proteins studied, as well as its
correlation with the prognosis of OSCC, was evaluated
using the χ2 test, with the level of significance set at 5% (α =
.05). The study was approved by the ethics committee of
UFRN (no. 65/06- 2006).3. Results
The immunoexpression of BMP-2/4 and of its receptor
BMPR-IA showed a typical cytoplasmic location, with
variations in the intensity of expression in the epithelial layer
depending on the type of tumor studied.
In the experimental group without metastasis (n = 16),
expression of BMP-2/4 was predominantly strong (n = 10,
62.5%) (Fig. 1, Table 1). Strong immunoreactivity to BMPR-F
Table 1
Distribution of the expression of BMP-2/4 in metastatic and nonmetastatic OSCC specimens
Group Total Qui2 P
Controle With
metastasis
Without
metastasis
n % n % n % n %
BMP-2/4 Staining
intensity
Weak 10 100 2 28.6 6 37.5 18 54.5 12.11 .002
Strong 0 0 5 71.4 10 62.5 15 45.5
Total 10 100 7 100.0 16 100.0 33 100.0
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the experimental group with metastasis (n = 7), strong
expression of BMP-2/4 was observed in most cases (n = 5,
71.4%) (Fig. 3, Table 1), whereas BMPR-IA exhibited weak
expression in 87.5% of the specimens analyzed (Fig. 4).
Weak expression of BMP-2/4 (Fig. 5, Table 1) and BMPR-
IA (Fig. 6) was observed in all 10 control cases of
fibroepithelial hyperplasia.
Statistical analysis showed a significant association
between the prognosis of OSCC and the intensity of BMP-
2/4 staining (P = .002) (Table 1). However, statistical
analysis was not possible in the case of BMPR-IA and,
therefore, the data were only analyzed descriptively.4. Discussion
During neoplastic development, BMPs can act as
oncogenes or as tumor suppressors depending on the stage
of the disease and their physiological concentration in the
tumor matrix [4]. In addition, the effects of BMPs are cell-
specific and may therefore vary between different types of
tumors, even those of the same cellular origin. Langenfeld et
al [10] also reported that the culture conditions of in vitro
studies, as well as the concentration of intra- and
extracellular antagonists, interfere with the biological
activity of BMPs.Fig. 2. Overexpression of BMPR-IA in nonmetastatic OSCC (arrows)
(original magnification ×400).Several investigators have demonstrated the expression of
BMPs and their receptors in different neoplastic processes.
In tumors of mesenchymal origin, BMPs are associated with
the pathologic formation of bone, calcified masses, and
chondroid tissue inside the tumor or at ectopic sites; in
addition, BMPs have been implicated in tumor progression
[11]. Kusafuka et al [12] investigated the expression of
BMPs in chondroid areas of 15 pleomorphic adenoma
specimens and observed frequent overexpression of BMP-2
in these regions. Jin et al [11] reported overexpression of
BMPs 2/4 and 5 and their receptor BMPR-IA in malignant
tumors of the oral epithelium. In addition, BMPs 2/4 and 5,
but not their receptors, have been implicated in the
development of metastasis in some cases of OSCC.
In the present study, expression of BMP-2/4 was weak in
the 10 (100%) control specimens analyzed, indicating that
the concentration of these proteins tends to be low in normal
differentiated tissues and benign pathologic processes as
previously reported [10,11,13,14]. Kusafuka et al [12] also
found low immunoreactivity to BMPs 1, 2, 3, 4, and 7 in
normal glandular epithelium. On the other hand, Kumamoto
and Ooya [15] reported significant expression of BMPs 2, 4,
and 7 and their receptors in normal odontogenic epithelium
of tooth germs during the late bell and crown stage, a fact
compatible with the active participation of BMPs in tooth
formation during postnatal animals development. Hardwick
et al [16] investigated the immunoexpression of BMP-2 inig. 3. Overexpression of BMP-2/4 in metastatic OSCC (arrows) (originalF
magnification ×400).
Fig. 4. Weak expression of BMPR-IA in metastatic OSCC (arrows) (original
magnification ×400).
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matous polyposis and observed the loss of BMP-2 expres-
sion in dysplastic areas of the microadenoma, when
compared to the superficial layer of normal epithelium
adjacent to the tumor that exhibited significant immunor-
eactivity. Kim et al [17,18] observed elevated expression ofFig. 5. Weak immunoexpression of BMP-2/4 in fibroepithelial hyperplasia
of the oral mucosa (arrows) (original magnification ×200).BMP receptors in normal prostatic and bladder tissue. These
studies suggest that the responsiveness to BMPs and their
receptors may vary among different cell types, including
those of the same embryonic origin.
In the present study, immunoreactivity to BMPR-IA was
low in the 10 control specimens analyzed (100%). This
finding can be explained by the same reasons stated above
for BMPs.
In the experimental group, strong expression of BMP-2/4
was observed in both metastatic (n = 5, 71.4%) and
nonmetastatic OSCC cases (n = 10, 62.5%). This finding
suggests disturbances in the signaling pathway mediated by
these proteins in the presence of malignant neoplastic
processes. This result agrees with Jin et al [11], Langenfeld
and Langenfeld [19], Kumamoto and Ooya [15], and Arnold
et al [20] who also observed strong expression of BMPs 2, 3,
5, and 6, especially BMP-2, in highly and poorly metastatic
breast cancer cell lines. Several studies have investigated the
probable causes for this overexpression of BMPs in
malignant neoplasms. According to Hsu et al [4], during
the initial stages of the disease, neoplastic cells tend to
increase the synthesis of BMPs in an attempt to inhibit cell
growth because BMPs are known to function as tumor
suppressors and therefore act directly on the cell cycle and
induce the apoptosis of altered cells. In this respect,
Kawamura et al [21] and Hjertner et al [22] investigated
the antiproliferative effect of BMP-2 and BMP-4, respec-
tively, on human multiple myeloma cells. The authors
suggested that these BMPs are able to inactivate STAT3
protein, a signal transducer activated by interleukin 6, and to
increase the expression of cell cycle inhibitors such as p21
and p27, with the consequent hypophosphorylation of pRb
and blockade of cell replication.
Hardwick et al [16] used colorectal cancer cell lines to
determine the role of BMP-2 in the development of this
cancer. The authors observed that BMP-2 reduced cell
growth, as demonstrated by the low expression levels ofig. 6. Weak immunoexpression of BMPR-IA in fibroepithelial hyperplasia
f the oral mucosa (arrows) (original magnification ×400).
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apoptosis and cell adhesion, as demonstrated by the high
levels of cleaved caspase-3 (a marker of apoptosis) and β-
catenin (an adhesion molecule). In an in vitro study, Wen et
al [23] reported that gastric cancer cell lines incubated with
BMP-2 for 4 to 5 days exhibited low levels of cell
proliferation and morphologic alterations characterized by
enlarged cells, an increase in intercellular contacts, and a
decrease in the nucleus-cytoplasm proportion. Recent studies
have suggested that the antiproliferative effect of BMPs
occurs in 3 steps: blockage of the cell cycle, stimulation of
apoptosis, and increase of cell adhesion.
In the present study, BMPR-IA showed variable expres-
sion in the experimental group. In metastatic OSCC
specimens, expression tended to be weak in all cases
analyzed. During carcinogenesis, especially in the more
advanced stages of the disease, neoplastic cells commonly
lose their responsiveness to BMPs, either due to the loss of
expression of their receptors or to the increased synthesis of
BMP inhibitors such as noggin [4,17,18,24]. The loss of
expression of BMP receptors, especially BMPR-IA, is
expected in many human cancers such as prostate, bladder,
breast, and intestinal colon cancer. However, in the case of
nonmetastatic OSCC, we observed a high expression of
BMPR-IA in all specimens studied. This finding suggests
the presence of responsiveness to BMPs and, consequently,
a trend of neoplastic cells to inhibit their own growth, thus
characterizing an antitumor effect of BMPs. According to
Hardwick et al [16] and Kim et al [18], the loss of BMP
receptor expression might be attributed to microsatellite
instability and the presence of mutations in the receptors, or
even to promotor suppression through methylation. In
contrast, several investigators reported the overexpression
of BMP receptors, a finding confirming that the function of
BMPs and their receptors varies among different cell lines and
tumors [11,15,20,23,25]. According to Hsu et al [4], these
receptors might be overexpressed but are inactive because of
the interaction with extracellular BMP antagonists, such as
noggin, which are overexpressed in more advanced stages of
tumor progression. Consequently, overexpressed BMPs no
longer act through an autocrine pathway, associated with an
antiproliferative effect, and start to act through a paracrine
pathway associated with a proangiogenic effect.
Bone morphogenetic proteins possess various mechan-
isms to stimulate angiogenesis. Bone morphogenetic protein-
2 acts as a potent chemotactic agent for monocytes, which
differentiate into tissue macrophages and secrete proangio-
genic cytokines such as VEGF. Bone morphogenetic protein-
2 also stimulates undifferentiated mesenchymal cells to
release P1GF (placental growth factor), a factor important for
the recruitment of hematopoietic and undifferentiated
endothelial cells under pathologic conditions such as
ischemia, inflammation, healing, and cancer [19,26].
According to Langenfeld and Langenfeld [19] and Raida et
al [26], BMPs act directly on endothelial cells by activating
Id1 (inhibitor of differentiation) and Erk-1/2 (signaltransducer in endothelial cells) triggered by the release of
VEGF. In addition, protein Id delays senescence of
endothelial cells.
In the present study, we observed a significant association
between BMP-2/4 expression and disease prognosis (P =
.002) (Table 1), whereas statistical analysis was not possible
in the case of BMPR-IA; however, a weak expression was
detected in most of cases of the metastatic group.
The data suggest that the strong expression of BMP-2/4,
associated with the weak expression of BMPR-IA, in the
metastatic group may have prognostic implications, with the
loss of responsiveness to BMPs through the loss of
expression of their receptors being indicative of the
development of metastasis in OSCC. In addition, the high
immunoreactivity to BMP-2/4 observed only in the experi-
mental group agrees with the trend toward overexpression of
these proteins in malignant neoplasms and consequent
disturbance in the BMP-mediated signaling pathway.
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